Corticotroph adenoma in the dog: Pathogenesis and new therapeutic possibilities

Research in Veterinary Science

Volumn 88, Issue 1, 2010, Pages 26-32

  Castillo, V A ^a   Gallelli, M F ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Corticotroph adenoma; Corticotrophinoma; Cushing's disease; Dog; Pituitary adenoma; Pituitary dependent hypercortisolism

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CABERGOLINE; GLUCOCORTICOID RECEPTOR; HOMEODOMAIN PROTEIN; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEIN P16; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; RETINOIC ACID;

ACTH SECRETING ADENOMA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CUSHING DISEASE; DOG; HUMAN; HYPERCORTISOLISM; NONHUMAN; PATHOGENESIS; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; ONCOGENES;

CANIS FAMILIARIS;

EID: 71649101049     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2009.07.005     Document Type: Review

References (95)

1. Agarwal M.K. The antiglucocorticoid action of mifepristone. Pharmacology and Therapeutics 70 (1996) 183-213
2. Ambrosi B., Aroiso M., Dall'Asta C., Cannavo S., Libe R., Vigo T., Epaminonda P., Chiodini I., Ferrero S., Trimarchi F., Arosio M., and Beck-Peccoz P. Effects of the chronic administration of the PPAR-γ receptor ligand, rosiglitazone, in Cushing's disease. European Journal of Endocrinology 151 (2004) 173-178
3. Akita S., Webster J., Ren S.G., Takino H., Said J., Zand O., and Melmed S. Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. Journal of Clinical Investigation 95 (1995) 1288-1298
4. Arnaldi G., Cardinaletti M., and Boscaro M. Advances in medical treatment of Cushing's disease. Expert Review Endocrinology and Metabolism 2 (2007) 735-743
5. Assa S.L., and Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocrine Reviews 19 (1998) 798-827
6. Barker E.N., Campbell S., Tebb A.J., Neiger R., Herrtage M.E., Reid S.W., and Ramsey I.K. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine 19 (2005) 810-815
7. Boscaro M., Barzon L., Fallo F., and Sonino N. Cushing's syndrome. The Lancet 357 (2001) 783-790
8. Brada M. The long term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Journal of Clinical Endocrinology 38 (1993) 571-578
9. Braddock J.A., Church D.B., Robertson I.D., and Watson A.D. Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism. Australian Veterinary Journal 82 (2004) 272-277
10. Bruyette, D.S., 1995. Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with L-deprenyl. In: Yu, P., Tipton, K., Boulton, A., (Eds.), Current Neurochemical and Pharmacological Aspects of Biogenicamines, Progress in Brain Research, vol. 106, pp. 207-215.
11. Buckley N., Bates A.S., Broome R.C., Strange R.C., Perret C.W., Burke C.W., and Clayton R.N. P53 protein accumulates in Cushings adenomas and invasive non-functional adenomas. Journal of Clinical Endocrinology and Metabolism 79 (1995) 1513-1516
12. Castillo V.A., Lalia J.C., Casal J., Casal G., Esarte M., Mira G., Rodriguez M., and Marquez A. Aminoglutetimide: alternativa terapéutica en caninos con Enfermedad de Cushing (hipófiso-dependiente). Avances en Medicina Veterinaria 11 (1996) 93-96
13. Castillo V.A., Giacomini D.P., Paez-Pereda M., Stalla J., Labeur M., Theodoropoulou M., Holsboer F., Grossman A., Stalla G., and Arzt E. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 174 (2006) 4438-4444
14. Castillo V.A., Gomez N.V., Lalia J.C., Cabrera Blatter M.F., and Garcia J.D. Cushinǵs disease in dogs: Cabergoline treatment. Research in Veterinary Science 85 (2008) 26-34
15. Chanson P., and Salenave S. Diagnosis and treatment of pituitary adenomas. Minerva Endocrinology 29 (2004) 241-273
16. Chen Y., Hu X., and Wei L. Molecular interaction of retinoic acid receptor with coregulators PCAF and RIP140. Molecular and Cellular Endocrinology 226 (2004) 43-50
17. Clayton R.N., and Farrell W.E. Clonality of pituitary tumours: more complicated than initially envisaged?. Brain Pathology 11 (2001) 313-327
18. Colao A., Lombardi G., and Annunziato L. Cabergoline. Experimental Opinion Pharmacotherapy 1 (2000) 555-574
19. Dahia P.L., and Grossman A.B. The molecular pathogenesis of corticotroph tumors. Endocrine Reviews 20 (1999) 136-155
20. Dasen J.S., O' Conell S.M., Flynn S.E., Treier M., Gleiberman A.S., Szeto D.P., Hooshmand F., Aggarwal A., and Rosenfeld M.G. Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell type. Cell 97 (1999) 587-596
21. de Bruin, C., Hanson, J.M., Meij, B.P., Kooistra, H.S., Waaijers, A.M, Uitterlinden, P, Lamberts,S.W.J., Hofland, L.J., 2008. Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine. Cushing's Disease Endocrinology 149, 4357-4366.
22. den Hertog E., Braakman J.C., Teske E., Kooistra H.S., and Rijnberk A. Results of non-selective adrenocorticolysis by o, p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. The Veterinary Record 144 (1999) 12-17
23. Dieterich K.D., Guldenkifinger E.D., Lüdecke D.K., and Lehnert H. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 (1998) 3327-3331
24. Engelhardt D., and Weber M.M. Therapy of Cushinǵs Syndrome with steroid biosyntesis inhibitors. The Journal of Steroid Biochemistry and Molecular Biology 49 (1994) 261-267
25. Engler D., Redei E., and Kola I. The corticotropin-release inhibitory factor hypothesis: a review of the evidence for existence of inhibitory as well as stimulatory hypophysiotropic regulation of adrenocorticotropin secretion and biosynthesis. Endocrine Reviews 20 (1999) 460-500
26. Evans C.O., Young A.N., Brown M.R., Brat D.J., Parks J.S., Neish A.S., and Oyesiku N.M. Novel pattern of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. Journal of Clinical Endocrinology and Metabolism 86 (2001) 3097-3107
27. Fracassi F., Gandini G., Diana A., Preziosi R., van den Ingh T.S., Famigli-Bergamini P., and Kooistra H.S. Acromegaly due to somatroph adenoma in a dog. Domestic Animal Endocrinology 32 (2007) 43-54
28. Giacomini D., Paez-Pereda M., Theodoropoulou M., Labeur M., Refojo D., Gerez J., Chervin A., Berner S., Losa M., Buchfelder M., Renner U., Stalla G.K., and Arzt E. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147 (2006) 247-256
29. Gsponer J., De Tribolet N., Déruaz J.P., Janzer R., Uské A., Mirimanoff R.O., Reymond M.J., Rey F., Temler E., Gaillard R.C., and Gomez F. Diagnosis, treatment and outcome of pituitary tumors and other abnormal intracellular masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 78 23 (1999) 6-269
30. Hanson J.M., Van't H.M., Voorhout G., Teske E., Kooistra H.S., and Meij B.P. Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine 19 (2005) 687-694
31. Hanson J.M., Teske E., Voorhout G., Galac S., Kooistra H.S., and Meij B.P. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. Journal of Neurosurgery 107 (2007) 830-840
32. Hanson J.M., Mola J.A., Leegwater P.A.J., Bilodeau S., Drouin J., and Meij B.P. Expression and mutation analysis of Tpit in the canine pituitary gland and corticotroph adenomas. Domestic Animal Endocrinology 34 (2008) 217-222
33. Heaney A.P., Fernando M., and Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. Journal of Clinical Investigation 109 (2002) 277-283
34. Heaney A.P., Fernando M., Yong W., and Melmed S. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nature Medicine 8 (2002) 1281-1287
35. Heaney A.P., Fernando M., and Melmed S. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. Journal of Clinical Investigation 111 (2003) 1381-1388
36. Hereñú C., Brown O., Sosa Y., Morel G., Reggiani P., Bellini M., and Goya R. The neuroendocrine system as a model to evaluate experimental gene therapy. Current Gene Therapy 6 (2006) 125-129
37. Hereñú C., Rimoldi O., Becú-Villalobos D., Cambiaggi D., Portiansky E., and Goya R. Restorative effect of insulin-like growth factor-I gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction. Gene Therapy 13 (2006) 1-9
38. Herman V., Fagin J., Gonsky R., Kovacs K., and Melmed S. Clonal origin of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 71 (1990) 1427-1433
39. Jacks T., Fazeli A., and Schmitt E.M. Effects of an Rb mutation in the mouse. Nature 359 (1999) 295-300
40. Kang H. Retinoic acid and its receptors repress the expression and transactivation functions of Nurr77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Experimental Cell Research 256 (2000) 545-554
41. Karl M., Lamberts S.W., Koper J.W., Katz D.A., Huizenga N.E., Kino T., Haddad B.R., Hughes M.R., and Chrousos G.P. Cushing's disease preceded by generalized glucocorticoid resistance. clinical consequences of a novel dominant negative glucocorticoid receptor mutation. Proceedings of the Association of American Physicians 108 (1996) 296-307
42. Karl M., Von Wichert G., Kempter E., Katz D.A., Reincke M., Monig H., Ali I.U., Stratakis C.A., Oldfield E.H., Chrousos G.P., and Schulte H.M. Nelson's Syndorme associated with somatic frame shift mutation in the glucocorticoid receptor gene. Journal of Clinical Endocrinology and Metabolism 81 (1996) 124-129
43. Kintzer P., and Peterson M. Mitotane (o,ṕ-DDD) treatment of 200 dogs with PDH. Journal Veterinary Internal Medicine 5 (1991) 182-190
44. Kovalovsky D., Refojo D., Liberman A.C., Hochbaum D., Paez Pereda M., Coso O.A., Stalla G.K., Holsboer F., and Arzt E. Activation and induction of Nur77/Nurr1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A and MAPK pathways. Molecular Endocrinology 16 (2002) 1638-1651
45. Lamberts S.W. Glucocorticoid receptors and Cushing's disease. Molecular and Cellular Endocrinology 197 (2002) 69-72
46. Lamolet, B., Poulin G., Chu, K., Guillemot, F., Tsai, M.J., Drouin, J., 2004.Tpit-independent function of NeuroD1(BETA2) in pituitary corticotroph differentiation. Molecular Endocrinology 18, 995-1003.
47. Lanctôt C.h., Gauthier Y., and Drouin J. Pituitary homebox 1 (Ptx1) is differentially expressed during pituitary development. Endocrinology 140 (1999) 1416-1422
48. Lei M., and Thé H. Retinoids and retinoic acid receptor in cancer. European Journal of Cancer Supplements 1 (2003) 13-18
49. Levy A., and Lightman S. Molecular defects in the pathogenesis of pituitary tumors. Frontiers in Neuroendocrinology 24 (2003) 94-127
50. Lidhar K., Korbonits M., Jordan S., Khalimova Z., Kaltsas G., Lu X., Clayton R.N., Jenkins P.J., Monson J.P., Besser G.M., Lowe D.G., and Grossman A.B. Low expression of the cell cycle inhibitor p27/kip1 in normal corticotroph cells, corticotroph tumors and malignant pituitary tumors. Journal of Clinical Endocrinology and Metabolism 84 (1999) 3823-3830
51. Lovekamp-Swan T., and Chaffin C.L. The peroxisome proliferator-activated receptor γ ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Molecular and Cellular Endocrinology 233 (2005) 15-24
52. Maira M., Martens C., Philips A., and Drouin J. Heterodimerization between members of the Nurr subfamily of orphan nuclear receptor as a novel mechanism for gen activation. Molecular and Cellular Biology 19 (1999) 7549-7557
53. Mampalam T.J., Tyrrell J.B., and Wilson C.B. Transphenoidal microsurgery for Cushing's disease: a report of 216 cases. Annals of Internal Medicine 109 (1988) 487-493
54. Martens C.H., Bilodeau S., Maira M., Gauthier Y., and Drouin J. Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nurr77 orphan nuclear receptors and glucocorticoid receptor. Molecular Endocrinology 19 (2005) 885-897
55. Meij B.P., Mol J.A., Bevers M.M., and Rijnberk A. Residual pituitary function after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. Journal Endocrinology 155 (1997) 531-539
56. Meij B.P. Hypophysectomy as a treatment for canine and feline Cushinǵs disease. Veterinary Clinics of North America 31 (2001) 1015-1041
57. Meij B., Voorhout G., and Rijnberk A. Progress in transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. General and Comparative Endocrinology 197 (2002) 89-96
58. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. Journal of Clinical Investigation 112 (2003) 1603-1618
59. Merino R., and Hurlé J.M. The molecular basis of retinoid action in tumors. Trends in Molecular Medicine 12 (2003) 508-511
60. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D.Y., and Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 85 (1996) 707-720
61. Nudi M., Ouimette J.F., and Drouin J. Bone morphogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. Molecular Endocrinology 19 (2005) 1329-1342
62. Ooi G.T., Tawadros N., and Escalona R.M. Pituitary cell lines and their endocrine applications. Molecular and Cellular Endocrinology 228 (2004) 1-21
63. Orth D.N., and Kovacs W. The adrenal cortex. Williams Textbooks of Endocrinology. ninth ed. (1998), W.B. Saunders Company, Philadelphia 569-572
64. Otte C., Lenoci M., Metzler T., Yehuda R., Marmar M.R., and Neylan T.C. Hypothalamic-pituitary-adrenal axis activity and sleep in posttraumtic stress disorder. Neuropsychopharmacology 6 (2005) 1173-1180
65. Páez-Pereda M., Missale C., Grübler Y., Arzt E., Scaf L., and Stalla G.K. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Molecular and Cellular Endocrinology 167 (2000) 99-106
66. Páez-Pareda M., Kovalovsky D., Hopfner U., Theodoropoulou M., Pagotto U., Uhl E., Losa M., Stalla J., Grübler Y., Missale C., Arzt E., and Stalla G.K. Retinoic acid prevents experimental Cushing syndrome. Journal of Clinical Investigation 108 (2001) 1123-1131
67. Petrossians P., Ronci N., Valdes Socin H., Kalife A., Stevenaert B., Bloch B., Tabarin A., and Beckers A. ACTH silent adenoma shrinking under cabergoline. European Journal of Endocrinology 144 (2000) 51-57
68. Philips A., Lesage S., Gingras R., Maira M.H., Gauthier Y., Hugo P., and Douin J. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Molecular and Cellular Biology 17 (1997) 5946-5951
69. Pivonello R., Ferone D., de Herder W., Kros J., de Caro M., Arvigo M., Annunziato L., Lombardi G., Colao A., Ho L., and Lamberts S. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 89 (2004) 2452-2462
70. Reichlin S. Neuroendocrinology. Williams Textbooks of Endocrinology. ninth ed. (1998), W.B. Saunders Company, Philadelphia 165-208
71. Reine N.J. Medical management of pituitary-dependent hyperadrenocorticism: mitotane VS trilostane. Clinical Techniques in Small Animal Practice 22 (2007) 18-25
72. Reusch C.E., Steffen T., and Hoerauf A. The efficacy of l-deprenyl in dogs with pituitary-dependent hyperadrenocorticism. Journal Veterinary Internal Medicine 13 (1999) 291-301
73. Ruckstuhl N.S., Nett C.S., and Reusch C.E. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. American Journal of Veterinary Research 63 (2002) 506-512
74. Savage J.J., Yaden B.C., Kiratipranon P., and Rhodes S.J. Transcriptional control during mammalian anterior pituitary development. Gene 319 (2003) 1-19
75. Seaholtz A. Regulation of adrenocorticotropic hormone secretion: lessons from mice deficinet in corticotropin-realising hormone. Journal of Clinical Investigation 105 (2000) 1187-1188
76. Sieber-Ruckstuhl N., Boretti F., Wenger M., Maser-Gluth C., and Reusch C. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane. Domestic Animal Endocrinology 31 (2006) 63-75
77. Sieber-Ruckstuhl N.S., Boretti F.S., Wenger M., Maser-Gluth C., and Reusch C.E. Serum concentration of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. The Veterinary Record 163 (2008) 477-481
78. Simmons N.E., Alden T.D., Thorner M.O., and Laws Jr. E.R. Serum cortisol response to transphenoidal surgery for Cushing's disease. Journal of Neurosurgery 95 (2001) 1-8
79. Sonino N., Fava G.A., and Boscaro M. A role for life events in the pathogenesis of Cushing's disease. Clinical Endocrinology (Oxford) 38 (1993) 261-264
80. Sonino N., Fava G.A., Fallo F., Franceschetto A., Belluardo P., and Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 3 (2000) 55-59
81. Sugawara A., Yen P.M., Qi Y., Lechan R.M., and Chin W.W. Isoform-specific retinoid-X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. Endocrinology 136 (1995) 1766-1774
82. Suh H., Gage P.J., Drouin J., and Camper S.A. Pitx2 is required at multiple stages of pituitary organogenesis: pituitary primordium formation and cell specification. Development 129 (2002) 329-337
83. Suri D., and Weiss R. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. Journal of Clinical Endocrinology and Metabolism 90 (2005) 1340-1349
84. Tanaka, S. 2003.Comparative aspects of intracellular proteolytic processing of peptide hormone precursors: studies of proopiomelanocortine processing. Zoological Science 20, 1183-1198.
85. Teshima T., Hara Y., Takekoshi S., Nezu Y., Harada Y., Yogo T., Teramoto A., Osamura R.B., and Tagawa M. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis. Domestic Animal Endocrinology 36 (2009) 32-44
86. Teshima T., Hara Y., Takekoshi S., Teramoto A., Osamura R.Y., and Tagawa M. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease. Domestic Animal Endocrinology 36 (2009) 3-12
87. Thibonnier M., Preston J.A., Dulin N., Wilkins P.L., Berti-Mattera L.N., and Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 138 (1997) 4109-4122
88. Treier, M., Gleiberman, A.S., O' Conell, S.M., Szeto, D.P., McMahon, J.A., McMahon, A.P., Rosenfeld, M.G., 1998. Multistep signaling requirements for pituitary organogenesis in vivo. Genes and Development 12, 1691-1704.
89. Vallette-Kasic S., Figarella-Branger D., Grino M., Pulichino A.M., Dufour H., Grisoli F., Enjalbert A., Drouin J., and Brue T. Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. Journal of Clinical Endocrinology and Metabolism 88 (2003) 2050-3056
90. Van Wijk P.A., Rijnberk A.D., Croughs R.J.M., Voorhout G., Sprang E.P.M., and Mol J.A. Corticotropin-releasing hormone and adrenocorticotropic hormone concentrations in cerebrospinal fluid of dogs with pituitary dependent hyperadrenocorticism. Endocrinology 131 (1992) 2659-2662
91. Wenger M., Sieber-Ruckstuhl N.S., Müller C., and Reusch C.E. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. American Journal of Veterinary Research 65 (2004) 1245-1250
92. Yano H., Readhead C., Nakashima M., Ren S., and Melmed S. Pituitary-directed leukaemia inhibitory factor transgene causes Cushing/s Syndrome neuro-immune-endocrine modulation of pituitary development. Molecular Endocrinology 12 (1998) 1708-1720
93. Zeugswetter F., Hoyer M.T., Pagitz M., Benesch T., Hittmair K.M., and Thalhammer J.G. The desmopressin stimulation test in dogs with Cushing's syndrome. Domestic Animal Endocrinology 34 (2008) 254-260
94. Zhang X., Horwitz G.A., Heaney A.P., Nakashima M., Prezant T.R., Bronstein M.D., and Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 (1999) 761-767
95. Zhou X.F., Shen X.Q., and Shemshedim L. Ligand activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jum/c-Fos dimerization. Molecular Endocrinology 13 (1999) 276-285